Wim H. J. Kruit
Erasmus University Rotterdam
98 Papers
1.2K Citations
Wim H. J. Kruit is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 37, co-authored 98 publications. Previous affiliations of Wim H. J. Kruit include Erasmus University Medical Center.
Chat about Author
Papers
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Alexander M.M. Eggermont,Stefan Suciu,Mario Santinami,Alessandro Testori,Wim H. J. Kruit,Jeremy Marsden,Cornelis J. A. Punt,François Sales,Martin Gore,Rona M. MacKie,Zvonko Kusić,Reinhard Dummer,Axel Hauschild,Elena Musat,Alain Spatz,Ulrich Keilholz +15 more
TL;DR: Adjuvant pegylated interferon alfa-2b for stage III melanoma has a significant, sustained effect on recurrence-free survival.
608
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Fernando Ulloa-Montoya,Jamila Louahed,Benjamin Dizier,Olivier Gruselle,Bart Spiessens,Frederic Lehmann,Stefan Suciu,Wim H. J. Kruit,Alexander M.M. Eggermont,Johan Vansteenkiste,Vincent Brichard +10 more
TL;DR: An 84-gene GS associated with clinical response for MAGE-A3 immunotherapeutic was identified in metastatic melanoma and confirmed in resected NSCLC, suggesting that their pretreatment expression influences the tumor's immune microenvironment and the patient's clinical response.
422
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Alexander M.M. Eggermont,Stefan Suciu,Rona M. MacKie,Wlodzimierz Ruka,Alessandro Testori,Wim H. J. Kruit,Cornelis J. A. Punt,Michelle Delauney,François Sales,Gerard Groenewegen,Dirk J. Ruiter,Izabella Jagiello,Konstantin Stoitchkov,Ulrich Keilholz,Danielle Lienard +14 more
TL;DR: Interferon alfa as used in the regimens studied does not improve outcome for patients with stage IIb/III melanomas, and cannot be recommended.
324
Side effects of interferon-α therapy
TL;DR: The toxicity profile of IFN-α, the presumed pathophysiology of the different side effects and the strategies to handle these are addressed and better identification of those patients who are likely to benefit from treatment without experiencing severe toxicities is lead to.
292